Futura Medical
Guildford, United Kingdom

Futura Medical is a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and a lead programme, MED3000, in development for erectile dysfunction.


Investment Perspective

Futura Medical is approaching a key point as the first of the regulatory filings for its novel erectile dysfunction (ED) treatment, MED3000, is expected within the next few months. MED3000 is a fast-acting gel that has proven clinical efficacy, a fast onset of action, and an attractive commercial profile. The ED market opportunity is sizeable, especially once MED3000 becomes widely available over the counter (OTC). Optimally addressing the various elements of the demographic segments and needs of the different geographies will, in our view, require careful selection of commercial partners. We expect the partnering discussions to start in earnest once the status of the regulatory approvals is known. Our DCF-based model, using conservative assumptions, values Futura Medical at £153.8m, equivalent to 60.9p a share.

Market information

SymbolPrimary exchanges


AGM statement confirms MED3000 filings on track
Update | 29 Jun 2020
Nearing the critical point in Erectile Dysfunction
Outlook | 02 Jun 2020
MED3000: more detail on FM57 results
Lighthouse | 02 Apr 2020

Recent News

Trading statement
24 Jun 2020
Futura files for Further FDA Pre-Submission meeting
20 Apr 2020
Futura confirms receipt of US FDA Minutes
06 Apr 2020
FY19 results
01 Apr 2020